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Background: A multifunctional telodendrimer-based micelle system was characterized for 
delivery of imaging and chemotherapy agents to mouse tumor xenografts. Previous optical 
imaging studies demonstrated qualitatively that these classes of nanoparticles, called nanomi-
celles, preferentially accumulate at tumor sites in mice. The research reported herein describes 
the detailed quantitative imaging and biodistribution profiling of nanomicelles loaded with a 
cargo of paclitaxel.
Methods: The telodendrimer was covalently labeled with 125I and the nanomicelles were loaded 
with 14C-paclitaxel, which allowed measurement of pharmacokinetics and biodistribution in the 
mice using microSPECT/CT imaging and liquid scintillation counting, respectively.
Results: The radio imaging data showed preferential accumulation of nanomicelles at the tumor 
site along with a slower clearance rate than paclitaxel formulated in Cremophor EL (Taxol®). 
Liquid scintillation counting confirmed that 14C-labeled paclitaxel sequestered in nanomicelles 
had increased uptake by tumor tissue and slower pharmacokinetics than Taxol.
Conclusion: Overall, the results indicate that nanomicelle-formulated paclitaxel is a poten-
tially superior formulation compared with Taxol in terms of water solubility, pharmacokinetics, 
and tumor accumulation, and may be clinically useful for both tumor imaging and improved 
chemotherapy applications.
Keywords: telodendrimer, nanomicelle, paclitaxel, microSPECT/CT, imaging guided drug 
delivery
Introduction
Cancer is primarily characterized by the uncontrolled proliferation of cells and their abil-
ity to metastasize. In spite of significant advances in the fight against cancer, it remains 
a challenging medical problem. Systemic chemotherapy is a common approach to the 
treatment of cancer. However, toxicity is a major side effect, which limits the utility and 
effectiveness of such nontargeted chemotherapeutics. Recent research in the development 
of drug delivery systems has focused on targeted delivery and controlled drug release at 
tumor sites in order to increase efficacy while reducing systemic toxicity. Imaging-guided 
drug delivery is considered a promising strategy to achieve this goal.1 Full implementation 
of imaging-guided drug delivery will require that drugs can be imaged or identified in 
the body as they enter the blood stream. The goal of imaging-guided drug delivery is to 
optimize local delivery of the therapeutic pharmaceutical agent to the target tissue and 
provide microanatomical and functional imaging feedback of the therapeutic process, 
as well as longitudinal treatment and monitoring.
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The explosive growth of biocompatible   nanotechnologies 
has made the clinical utilization of molecular imaging and 
therapy with a host of novel agents a realistic near-term 
  possibility. Various nanocarriers, such as superparamagnetic 
iron oxide nanoparticles,2,3 gold nanoparticles,4 liposomes,5 
and polymeric nanoparticles6 loaded with large payloads of 
imaging agents, enable detection of cancer with standard 
imaging equipment via passive or active tumor-targeting 
effects. In order to fulfill the goal of imaging-guided drug 
delivery, nanocarriers need to be multifunctional, thus 
making them useful for both imaging and drug delivery. 
Our group has developed a well-defined and biocompatible 
amphiphilic telodendrimer system composed of polyethylene 
glycol (PEG), cholic acid, and a dendritic lysine core that 
can self-assemble into multifunctional water-soluble nano-
micelles to enable efficient delivery of hydrophobic cargos 
such as paclitaxel and the hydrophobic dye, 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindodicarbocyanine perchlorate.7,8 
Telodendrimers are easily labeled with fluorophores and 
radionuclides by covalent conjugation onto a lysine side 
chain at the junction site between the PEG and the cholic 
acid cluster, without compromising their propensity to form 
nanomicelles. For noncovalent labeling, telodendrimers can 
be mixed with radio-labeled drugs or fluorescent probes 
during nanomicelle formation.7 The tailored multifunctional 
features of the telodendrimer-based nanomicelle system are 
ideal for imaging-guided drug delivery applications.
Previous reports7,8 have demonstrated efficient tumor 
targeting and drug delivery by nanomicelles through optical 
imaging and efficacy studies using ovarian cancer xenograft 
models. Our nanomicelles were prepared via self-assembly 
of telodendrimers containing a linear 5 kDa PEG covalently 
attached to a dendritic lysine core with eight cholic acid 
groups (PEG5kCA8). In order to characterize and quantita-
tively analyze the biodistribution and tumor targeting effect 
of nanomicelle nanocarriers further, the telodendrimer was 
radiolabeled with 125I using the Bolton-Hunter reagent, which 
allowed in vivo microSPECT/CT imaging studies. In separate 
experiments,14C-labeled paclitaxel (14C-PTX) was loaded into 
the nanomicelles (14C-PTX-NM) and administered to mice 
bearing tumors in order to elucidate the tumor-targeting, 
biodistribution, and pharmacokinetic profiles of the drug 
cargo sequestered in the nanocarrier. Comparison of both 
the imaging and quantitative biodistribution profiles of pacli-
taxel loaded into nanomicelles will aid in understanding and 
optimizing the telodendrimer system for better targeting of 
systemic cancer therapies.
Materials and methods
Paclitaxel
14C-PTX was purchased from Moravek Biochemicals Inc, 
(Brea, CA). Unlabeled paclitaxel was purchased from AK 
Scientific (Union City, CA). A Cremophor EL formulation of 
paclitaxel (Taxol®) from AK Scientific (Mountain View, CA) 
was obtained from the UC Davis Cancer Center pharmacy.
Cell lines
Ovarian cancer (SKOV-3) cell line was obtained from the 
American Type Culture Collection (Manassas, VA). The 
cells were maintained in Macoy-5A media and split every 
3–4 days.
Mouse ovarian cancer xenograft model
The animal studies were performed according to a pro-
tocol approved by the Institutional Animal Care and Use 
Committee of the University of California, Davis. Female 
athymic nude mice (nu/nu), obtained from Harlan Inc, 
  (Indianapolis, IN) at 5–6 weeks of age, were injected sub-
cutaneously in the right flank with 5 × 106 SKOV-3 cells 
suspended in 200 µL of phosphate-buffered saline. When 
the subcutaneous tumors reached 0.5–1.0 cm in diameter or 
14–21 days after implantation, the tumor-bearing mice were 
subjected to microSPECT/CT imaging of the  125I-labeled 
nanomicelles or biodistribution studies of the 14C-PTX loaded 
nanomicelles.
Iodination of telodendrimers and micelles
Iodination of telodendrimers was accomplished via the 
125I-Bolton-Hunter reagent, which was provided by Perkins 
Elmer through custom radiolabeling. Excess Bolton-Hunter 
reagent was removed by passage through an LH-20 size 
exclusive column using ethanol as the eluent, yielding 
10 mCi of  125I-labeled telodendrimers with a radioactive 
purity of 99.1%.
Preparation of the paclitaxel-loaded 125I-labeled nanomi-
celles (PTX-125I-NM) was as follows: 3.2 mg of paclitaxel and 
32 mg of PEG5kCA8 telodendrimer were dissolved in 2 mL of 
chloroform. Immediately after mixing, 0.8 mCi of 125I-labeled 
PEG5kCA8 solution in ethanol (0.32 mL) was added. The solu-
tion was dried via nitrogen blowing overnight in a radio safety 
fume hood. Phosphate-buffered saline 1.6 mL was added and 
the mixture was vortexed for 30 seconds and sonicated for 
30 minutes to disperse the complex into micelles. The ratio 
of 125I-labeled to unlabeled PEG5kCA8 in the paclitaxel-loaded 
nanomicelles was 1:800 by mass.
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MicroSPECT/CT imaging 
MicroSPECT/CT imaging of PTX-125I-NM in a human 
  ovarian cancer xenograft model was performed at the 
Center for Molecular and Genomic Imaging, University of 
California, Davis. Nude mice bearing SKOV-3 xenografts 
were injected with 200 µL of 100 µCi   paclitaxel-loaded 
PTX-125I-NM (400 µg of paclitaxel in 4 mg of PEG5kCA8) 
via the tail vein. Pinhole SPECT images were acquired at 
hours 1, 5, 18, 24, 48, 72, and 94 following injection. SPECT 
images were acquired using the InveonMM (Siemens Pre-
clinical Solutions, Knoxville, TN). The collimator set used 
was the mouse medium energy collimator, which is a single 
pinhole with a 3 mm diameter. The scanner has two SPECT 
heads that rotate around the animal. The radius of rotation 
was set at 40 mm. This collimator and radius combina-
tion yields a spatial resolution of approximately 3.5 mm. 
A total of 20 projections were acquired over 180 degrees 
per SPECT head and the initial projection exposure time 
was 150 seconds. The exposure time at each projection is 
adjusted for nuclide decay to yield an equivalent number 
of counts per projection. List mode data are collected, 
including all photon events, and photon energy is recorded. 
The data were reconstructed with an energy cut of 
28–42 keV.   The images were reconstructed with OSEM 
using four subsets and 20 iterations. Low resolution CT 
images were acquired for anatomical   registration with 
the SPECT images. The images are displayed as a 
percent of the maximum voxel in the image. All images were 
scaled to 100 as the maximum intensity value.
14C-PTX-NM preparation
The micelles were formulated in a manner similar to the 
protocol used above, except without  125I-labeling. Briefly, 
4 µCi of 14C-PTX in ethyl acetate was added to 5 mL of 
chloroform solution containing 15 mg of unlabeled paclitaxel 
and 100 mg of PEG5kCA8 telodendrimer. The solution was 
dried by nitrogen blowing overnight, followed by addition 
of 5 mL of phosphate-buffered saline and vortex mixing 
for 30 seconds and sonication for 30 minutes. The ratio of 
radiocarbon-labeled and unlabeled paclitaxel in the resulting 
micelle formulation was approximately 1:1100 by mass.
Doping of Taxol with  14C-PTX (14C-PTX-Taxol) was 
achieved as follows: 3 µCi of  14C-PTX in ethyl acetate 
was added to 1.875 mL of Taxol (6 mg paclitaxel/mL) 
and vortexed for 30 seconds. The Cremophor solution of 
Taxol was then diluted with phosphate-buffered saline to 
a final paclitaxel concentration of 1.5 mg/mL. The ratio of 
radiocarbon-labeled and unlabeled paclitaxel in the resulting 
micelles was approximately 1:1100 by mass.
14C-PTX biodistribution
Nude mice bearing SKOV-3 xenografts were injected with 
200 µL solutions containing of 100 µCi  14C-PTX-NM   
(400 µg total mass of paclitaxel that was mixed with 4 mg of 
PEG5kCA8 prior to nanomicelle synthesis) via the tail vein. 
The major organs and tissues collected were whole blood, 
brain, skin, heart, lung, liver, spleen, kidney, bladder, muscle, 
and tumor. The time points of data collection were at hours 
0, 0.5, 1, 6, 16, 24, 48, and 72. At selected time points, blood 
was collected by heart puncture under temporary anesthesia 
with ether. After blood collection, the mouse was euthanized 
by cervical dislocation. All organs were collected and weighed, 
put into 1.5 mL Eppendorf centrifuge tubes, and kept on ice 
prior to homogenization. Organs and tissue were minced into 
chunks of approximately 1 mm in diameter. The minced tissue 
was then added to 1 mL of Biosol, agitated gently, and placed in 
an incubator shaker at 50°C and shaken for 6 hours at 650 rpm. 
When chunks of tissue were no longer visible in the suspen-
sion, all the solution in the tubes were transferred into 20 mL 
scintillation vials, and decolorized by addition of 0.2 mL of 
30% hydrogen peroxide. The vials were capped loosely and 
incubated at 50°C for one hour. Finally, 18 mL of liquid scintil-
lation counting cocktail was added into each scintillation vial, 
followed by running the samples in a Packard 1500 Tri-Carb 
liquid scintillation analyzer with standard protocols for radio-
carbon detection. Data were processed on an Excel spreadsheet 
running Solutions pharmacokinetic software.
Data processing and statistics
For determination of the radiointensity of tumors and   normal 
organs in the radioimaging, we calculated the average 
  values of the tumor area and of the normal organ area using 
the three-  dimensional regions of interest function of the 
  Siemens microPET ASIPro WM 6.7.1.2 software program. 
All data are shown as the mean ± standard deviation of three 
independent measurements. The Student’s t-test was used 
for statistical analysis of the radioimaging intensity and 
pharmacokinetic data. Statistical significance was indicated 
by P , 0.05 and P , 0.001.
Results and discussion
MicroSPECT/CT imaging of nanomicelles
Our previous research has demonstrated excellent tumor 
targeting of telodendrimer-based nanomicelles using near-
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infrared fluorescence imaging, whereby nanomicelles 
formed by PEG5kCA8 are loaded with the near-infrared dye, 
1,1′-dioctadecyl-3,3,3′,3′-tetramethyl indodicarbocyanine 
perchlorate, and paclitaxel.7,8 Near-infrared fluorescence 
imaging offers unique advantages for diagnostic imaging 
of solid tumors with high sensitivity,9 given the low in vivo 
autofluorescence in the near-infrared range (700–900 nm) 
and the minimal near-infrared absorbance by biological 
components, such as hemoglobin, water, and lipids.10,11 
However, near-infrared fluorescence imaging is not quanti-
tative and has a limited penetration distance, as well as low 
spatial resolution.12 In contrast, radioimaging is superior for 
quantification due to good tissue penetration of gamma rays 
and the ability to measure count rates in tissue accurately, 
permitting whole body quantitative imaging not only in small 
animals, but also in humans.
For this report, radioimaging was performed using an 
established tumor xenograft model. The PEG5kCA8 teloden-
drimer was labeled with 125I via the Bolton-Hunter reagent 
as shown in Scheme 1A. The unbound labeling reagent was 
removed by passage through a size-exclusive column, with 
ethanol as the eluent to avoid formation of telodendrimer 
aggregates in which the iodination reagent could become 
trapped. The 125I-labeled telodendrimer was doped into a solu-
tion of unlabeled telodendrimers and loaded with paclitaxel 
during self-assembly according to a previously published 
protocol.7,8 Doses of PTX-125I-labeled nanomicelles were 
injected into nude mice bearing SKOV-3 xenografts. As 
shown in Figure 1, decay-corrected imaging indicated that 
the PTX-125I-NM accumulated specifically and continuously 
at the tumor site and reached a peak at around 18–24 hours 
post injection. The tumor signal then decreased gradually, 
with substantial retention of nanomicelles in the tumor with 
respect to background tissue for up to 94 hours post injec-
tion. Within the first 5 hours, the majority of the 125I-labeled 
material was observed in the blood circulation of the mouse 
and in the blood-rich organs of the chest and upper abdomen. 
The signal within normal organs, such as the heart, lung, 
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Scheme 1 Radioformulated nanomicelle. (A) Structure of the 125I-labeled telodendrimer PEg5kCA8 and PTX-125I-NM for in vivo microSPECT imaging. (B) Structure of the 
parent telodendrimer PEg5kCA8 and self-assembled micelles loaded with paclitaxel doped with 14C-PTX. 
Abbreviations: 14C-PTX, 14C-labeled paclitaxel; NM, nanomicelles; PEg, polyethylene glycol; CA, cholic acid; PEg5kCA8, dendritic lysine core and eight cholic acid groups.
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and liver, was dramatically higher than that in tumor tissue. 
For 18–24 hours post injection, the signal in the tumor tissue 
was significantly (P , 0.05) higher than in most of the rest of 
body. Forty-eight hours post injection, significant retention of 
PTX-125I-NM persisted at the tumor site. Whole body projec-
tion images (Figure 2) showed the tumor to be the brightest 
part of the whole body at 72 hours post injection. In general, 
the tumor-targeting profile demonstrated by radioimaging 
is consistent with previous results from optical imaging, 
in which the telodendrimer was fluorescently labeled with 
BODIPY, a hydrophobic near-infrared dye.13 This finding 
supports previous observations that nanomicelles are able 
to target the tumor site via the enhanced permeability and 
retention effect associated with porous tumor vasculature, 
which enables nanomicelles to release their cargo into local-
ized tumor regions.
Quantitative analysis of the imaging data was performed 
in order to study the distribution profiles of PTX-125I-NM 
further in normal organs and tumor tissue. The radio signal 
in the blood pool refers to the signal calculated from the 
heart cavity. Other normal organs, such as the liver, lung, and 
muscle, were analyzed in addition to tumor tissue. Dominant 
125I accumulation was shown in the blood pool, liver, and 
lung within 24 hours. Distribution of 125I in the liver was 
much higher than that in tumor tissue for 5 hours post injec-
tion (Figure 3A), which is probably due to the high content 
of blood in the liver. Early accumulation in normal tissues, 
including muscle, had washed out quickly by one hour post 
injection. However, uptake in tumor tissue increased gradu-
ally and reached a plateau at 18–24 hours, then decreased 
slowly. This contrast in accumulation between tumor and 
normal tissue is consistent with enhanced permeation and 
retention-mediated accumulation of nanomicelles in tumor 
tissue. The 125I signal in normal organs and tumor over time 
was normalized by the signal in muscle to reflect the relative 
distribution and kinetic profiles. The signal change in muscle 
is usually in response to the basic clearance profile of the 
injected PTX-125I-NM. Therefore, the signal in tumor tissue 
or organs normalized by the signal from muscle will subtract 
interference from the background to highlight accumulation 
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Figure 1 Decay-corrected microSPECT/CT imaging of nude mice bearing SKOV-3 ovarian cancer xenograft (red arrow) after PTX-125I-NM was injected through the tail vein. 
After injection of PTX-125I-NM, microSPECT/CT images were taken at hours 1, 5, 18, 24, 48, 72, and 94. The panels show nanomicelle accumulation in tumor tissue with time, 
which reached its highest level at around 18–24 hours post injection, and then washed out gradually. The normal organs, including the heart, liver, and lung, demonstrated 
much higher uptake than tumor tissue within the first hour, but the signal decreased dramatically thereafter compared with that in tumor tissue. 
Abbreviations: PTX, paclitaxel; NM, nanomicelles; PEg, polyethylene glycol; CA, cholic acid.
Back to front Left to right Front to back Right to left
10000
0
Figure 2 Projection microSPECT/CT imaging of nude mice bearing SKOV-3 xenografts (red arrow) 72 hours post injection. In four different projection positions, the ovarian 
cancer xenograft showed much greater uptake of nanomicelles in comparison with the rest of the body at 72 hours post injection.
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and clearance trends of PTX-125I-NM in tumor tissue or 
organs. In addition, it will facilitate comparison between 
tumor tissue and normal organs. The normalized results 
indicate that the blood pool/muscle ratio was higher than the 
ratios from other organs and tumor tissue within 24 hours, but 
decreased rapidly to the background level by 48 hours. The 
ratio of lung/muscle remained constant, reflecting the similar 
clearance profile of the 125I-labeled substance in lung and 
muscle. However, the ratio of tumor/muscle kept increasing 
over time, indicating gradual accumulation and much slower 
clearance of the nanoparticles from tumor tissue. The liver/
muscle ratio slightly increased over time, probably owing to 
the   reticuloendothelial system in the liver that continuously 
takes up the  125I-labeled materials remaining in the body 
(Figure 3B).
Comparison of biodistribution  
of 14C-PTX-NM and 14C-PTX-Taxol
An understanding of the fate and biological effects of nano-
particles in animals is critical to their medical applications 
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Figure 3A Distribution of PTX-125I-NM in major organs and tumor tissue based on quantification of images. Within 24 hours, the radioactive signal in the blood pool was much 
higher than in the rest of the body and decreased rapidly to background levels by 48 hours. The liver and lung showed higher uptake of PTX-125I-NM than tumor tissue for one hour, 
but decreased very rapidly within 48 hours. However, radio signal accumulation in the tumor tissue increased to a peak within 24 hours, then decreased gradually thereafter. 
Notes: *P , 0.05; **P , 0.01. 
Abbreviations: PTX, paclitaxel; NM, nanomicelles.
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Figure 3B Imaging intensity ratio of normal organs and tumor tissue versus muscle. 
The ratio of blood pool/muscle was highest shortly after injection, but kept decreasing dramatically to the background level of radioactivity within 48 hours. The ratio of 
lung/muscle did not increase noticeably. The tumor/muscle ratio increased much faster over 90 hours than the liver/muscle ratio, even though it was lower than that of liver/
muscle initially (within 24 hours).
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in vivo. Pharmacokinetic and organ/tissue distribution 
properties of nanoparticles are of great interest from the 
clinical point of view because of their potential uses in   cancer 
  imaging and therapy. Systematic studies are required to evalu-
ate the distribution of administered nanoparticles inside the 
body, especially at the tumor site, after injection.
The use of 14C-PTX enabled us to quantify the drug and 
its metabolites within the mouse tissue and organs accurately 
via liquid scintillation counting after intravenous adminis-
tration. Because the predominant metabolites of paclitaxel 
include 3′-p-hydroxypaclitaxel, 6α-hydroxypaclitaxel, and 
6α,3′-p-dihydroxypaclitaxel, without any metabolic loss of 
carbon atoms from the parent molecule, we assume that the 
radiocarbon measurements accounted for all of the parent 
paclitaxel and its metabolites present in each sample.14 In 
order to study the effects of formulation into nanomicelles 
on the distribution of paclitaxel, 14C-PTX was loaded into 
nanomicelles and injected into nude mice bearing SKOV-3 
xenografts. As a benchmark for comparison, a small amount 
of 14C-PTX was added to Taxol, a Cremophor EL formula-
tion of paclitaxel used in the clinic, which was also admin-
istered to the tumor-bearing mice. The tissues and organs 
were harvested at various time points after injection. The 
14C concentration in blood and tissues was determined by 
liquid scintillation counting, which allowed calculation of 
total paclitaxel using the specific activity of each dose as a 
conversion factor. As shown in Figure 4, the biodistribution 
profiles of the  14C-PTX-NM in different organs and 
tumor tissue were similar to that of  14C-PTX-Taxol. Both 
  formulations showed low brain uptake of paclitaxel, indicat-
ing a general lack of accessibility because of the blood-brain 
barrier. At the zero time point, blood was withdrawn by 
heart puncture within one minute of intravenous injection of 
the 14C-labeled drug formulation. Organs and tumor tissue 
were harvested immediately after euthanasia. Samples from 
all subsequent time points were harvested using the same 
procedure. Figure 4A shows that 14C uptake in most of the 
organs reach a maximum within minutes, followed by rapid 
washout of drug, as was observed in the 125I   experiments. In 
contrast, the concentration of paclitaxel and its metabolites 
showed slower accumulation in tumor tissue, and reached 
a peak at around 30 minutes post injection, which then 
decreased slowly compared with normal tissues. The pacli-
taxel concentration in tumors of animals treated with the 
telodendrimer nanomicelle formulation was significantly 
(P , 0.05) higher than that in other organs, even in the liver, 
after 24 hours, which is consistent with the microSPECT/
CT imaging results. Tumor uptake in animals treated with 
14C-PTX-Taxol was also observed to increase within the first 
hour and to decrease gradually to a level similar to that in 
other organs, including skin, lung, and liver (Figure 4B). It 
is known that Taxol, which is a Cremophor EL (surfactant) 
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Figure 4A Biodistribution of 14C-labeled paclitaxel loaded into nanomicelles in nude mice with SKOV-3 xenografts. 
14C-PTX-NM showed much higher uptake in normal organs, including the spleen, heart, lung, kidney, and in particular the liver, than in tumor tissue in the beginning, but decreased 
very rapidly within 16 hours. 14C-PTX-NM accumulation in tumor tissue reached a peak at 30 minutes post injection, then decreased gradually, and showed higher levels than 
that in all normal organs 16 hours post injection. 
Abbreviations: 14C-PTX, 14C-labeled paclitaxel; NM, nanomicelles.
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formulation of paclitaxel, can also form micelles of about 
10 nm in size upon dilution in water or biological fluids. 
Therefore, Taxol also has a relatively long circulation time 
and is able to target tumor tissue via the enhanced permeation 
and retention effect. The biodistribution of Taxol in rodents 
has been described in tumor-bearing mice before. Liver and 
tumor have shown high paclitaxel concentrations at 24 hours 
after administration.15 Similar distribution behavior has also 
been observed with 111In-labeled paclitaxel.16 However, the 
stability of paclitaxel dissolved in Cremophor EL is poor in 
vitro upon dilution, as shown in our experiments. Paclitaxel 
has a tendency to leak out from the Cremophor micelles, 
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Figure 4B Biodistribution of 14C-labeled paclitaxel in Taxol® in nude mice with subcutaneous ovarian SKOV-3 xenografts. 
14C-PTX (Taxol) accumulation in tumor tissue reached a peak at one hour post injection, then decreased gradually, showing levels close to those in normal organs 16 hours post 
injection. 14C-PTX showed much higher uptake in normal organs, including the heart, spleen, lung and kidney, especially in the liver, compared with tumor tissue in the beginning, 
but decreased very rapidly within 24 hours. 
Abbreviation: 14C-PTX, 14C-labeled paclitaxel.
18
16
12
10
N
o
r
m
a
l
 
o
r
g
a
n
s
 
a
n
d
 
t
u
m
o
r
/
m
u
s
c
l
e
8
0
01
Time (h)
15 40 65 90
14
6
2
4
Brain
Skin
Heart
Lung
Liver
Spleen
Kidney
Blood
Tumor
Figure 5A Normalized biodistribution of 14C-labeled paclitaxel loaded into nanomicelles in nude mice with SKOV-3 xenografts (organs/muscle). 
The ratio of liver/muscle decreased dramatically within 16 hours post injection, even though it showed the highest ratio in the beginning. The ratio of skin/muscle increased 
up to around 5-fold. The ratio of tumor/muscle kept increasing to a peak of around 8.5-fold and showed much higher levels than those of organs/muscle after 16 hours.
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and crystals of paclitaxel were observed in the diluted Taxol 
solution (20× dilution by phosphate-buffered saline), whereas 
the telodendrimer nanomicelles loaded with paclitaxel at the 
same dilution remained very stable in size and solubility 
over months.
To demonstrate the relative trend of 14C-PTX uptake in 
different organs and tumor tissue, all values were normal-
ized to muscle  14C levels for each time point, except in 
blood (  Figure 5). Most organ ratios displayed continuously 
decreasing radiocarbon ratios, except for skin, elimina-
tion from which was slow compared with muscle, which 
is consistent with the high lipophilicity of paclitaxel. For 
14C-PTX-NM, the tumor/muscle ratio of radiocarbon 
content kept increasing and reached a plateau at approxi-
mately 8.5-fold 24–48 hours post injection. However, the 
normalized tumor/muscle ratio of 14C-PTX-Taxol showed 
an increase of only 3.5-fold at the highest point (Figure 5B), 
which is much lower than that when 14C-PTX was loaded 
in nanomicelles. Furthermore, the ratio of tumor/ muscle 
(14C-PTX-Taxol) was even lower than that of the skin/muscle 
ratio at earlier time points at least 24 hours post injection 
(Figure 5B). These observations indicated that telodendrimer 
nanomicelles enhanced the uptake of paclitaxel by tumor 
tissue.
The whole blood pharmacokinetic profile of paclitaxel 
after administration of  14C-PTX-NM or  14C-PTX-Taxol 
at dose levels of 15 mg/kg was calculated using a one-
  compartment model (Figure 6). A t = 0 time point was used 
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Figure 5B Normalized biodistribution of 14C-labeled paclitaxel in Taxol® in nude mice with SKOV-3 xenografts (organs/muscle). 
The ratio of liver/muscle showed higher levels for 6 hours post injection, but decreased rapidly at later time points. The ratio of skin/muscle kept increasing to a plateau at 
6 hours post injection, and decreased after 24 hours. This was even higher than the ratio of tumor/muscle most of the time, and was only around 3.5-fold at its peak.
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Figure 6 Pharmacokinetic data for paclitaxel formulated in nanomicelles and Taxol®. 
The terminal half-life (t1/2 70.3 hours) of paclitaxel loaded into PEg5kCA8 micelles was significantly longer than that for Taxol (t1/2 46.6 hours, P , 0.05). The area under the 
curve for PTX-NM was slightly higher, indicating modestly longer systemic exposure to the drug as a result of the nanomicelle formulation. 
Abbreviations: PTX, paclitaxel; NM, nanomicelles.
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to determine the maximum concentration of paclitaxel, which 
was 55 µg/mL for nanomicelles and 21 µg/mL for Taxol. 
The calculated initial absorption/distribution (t1/2α ) and 
terminal (t1/2β ) half-lives were 1.9 hours and 70 hours, 
respectively, for nanomicelles, and 3.1 hours and 47 hours, 
respectively, for Taxol (Table 1). The area under the blood 
concentration-time curve for the nanomicelles was similar 
to that for Taxol (21.8 µg-hours/mL and 18.3 µg-hours/mL, 
respectively). The blood half-lives for Taxol were similar 
to values reported for nude mice, except for the terminal 
half-life, which was previously reported to be 17 hours in 
plasma.17 The long terminal half-lives for both formulations 
in this report are consistent with paclitaxel uptake into blood 
cells, which is not accounted for in typical plasma or serum 
pharmacokinetic data. Although the initial whole blood 
absorption and distribution kinetics were faster for Taxol, the 
nanomicelle formulation persisted at higher concentrations 
at the later time points, possibly accounting, in part, for its 
improved preclinical efficacy.7,18–20
The longer half-life of PTX-NM compared with Taxol is 
consistent with slower hepatic elimination as a consequence 
of the 10–100 nm size of the nanomicelle nanocarrier.8 The 
slower blood terminal half-life observed for the nanomicelles 
is consistent with the slower hepatic filtration of the nano-
particle formulation, which has been previously reported 
for other nanoparticle-mediated drug delivery systems.21,22 
The paclitaxel clearance of 805 L/hour/kg for the Taxol 
formulation was reduced to 687 L/hour/kg for the PTX-NM 
formulation. Despite the fact that higher blood levels are 
reached when paclitaxel is given in the Taxol formulation, 
the tissue levels were essentially similar for both of the tested 
drug preparations.
It has to be noted that two different radiolabeling strate-
gies were used in this research, in which the radio isotope 125I 
was conjugated to telodendrimers for the SPECT imaging 
study and 14C-PTX was loaded inside nanomicelles for the 
pharmacokinetic experiments. There was a high radioactive 
signal found in the bloodstream during the first 24 hours in 
the microSPECT/CT images (Figures 1 and 3A). However, 
in the pharmacokinetic study, 14C-PTX-NM showed much 
less accumulation in the bloodstream than in the rest of 
the body, except for muscle, even within one minute post 
injection (Figure 4A). One explanation for this is that the 
current nanomicelle formulation is not stable in blood and 
that the nanomicelles disassemble partially and the loaded 
drug begins to release from the nanomicelles immediately 
after in vivo administration and diffusion into normal organs, 
resulting in a rapid decrease of 14C-PTX in the circulation.23,24 
In contrast, the 125I-telodendrimers, even if coming from dis-
sociated nanomicelles, still remain in the blood circulation 
for a longer time, contributing to a much higher radioactive 
signal in the blood during the 24 hours post injection.
We recently reported on the development of disulfide or 
boronate-catechol cross-linked nanomicelles23,24 that are much 
more stable than the non-crosslinked micelles reported here. 
The main advantage of crosslinked micelles is that premature 
drug release in the circulation can be minimized. Furthermore, 
disulfide reduction can occur inside the tumor cells with high 
glutathione levels, or on demand with exogenously adminis-
tered N-acetyl cysteine, a US Food and Drug Administration 
approved reducing agent. Similarly, the bornate catechol cross-
linkages can be reversed with the acidic environment at the 
tumor site and inside the endosomes of the tumor cells, or with 
exogenously administered mannitol, an approved diuretic. As 
a result, such crosslinked nanomicelles may be therapeutically 
more efficacious than non-crosslinked micelles.23,24 Work is 
underway in our laboratory using the techniques described in 
this study to determine the biodistribution and pharmacokinet-
ics of such crosslinked nanomicelles.
Conclusion
The tumor-targeting properties of the telodendrimer 
PEG5kCA8 nanomicelle system have been previously dem-
onstrated through near-infrared fluorescence optical imaging 
with improved preclinical outcomes compared with Taxol 
and Abraxane®. MicroSPECT/CT imaging enabled by 
125I-labeling of the nanomicelles further verified the highly 
efficient tumor targeting of the nanomicelles and provides a 
potential nanoplatform for cancer imaging and diagnosis. The 
biodistribution study of 14C-PTX indicates that sequestration 
Table 1 Pharmacokinetic parameters for paclitaxel in whole blood
Dose level 
(mg/kg)
Formulation Cmax 
(ng/mL)
AUC 
(ng-h/mL)
Elimination Vd 
(L/kg)
CI 
(L/h/kg) k 
(1/h)
t1/2(beta) 
(h)
t1/2(gamma) 
(h)
15 PTX-NM 54730 21827 0.317 1.91 70.3 69758 687
15 PTX-Taxol 20922 18306 0.153 3.15 46.6 54093 805
Abbreviations:  AUC,  area  under  the  concentration-time  curve;  Cmax,  peak  plasma  concentration;  Vd,  volume  of  distribution;  Cl,  clearance;  PTX,  paclitaxel; 
NM, nanomicelles.
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of the drug in the PEG5kCA8 nanomicelle system markedly 
prolongs the paclitaxel circulation time in blood and improves 
the uptake of paclitaxel at the tumor site. The liver was the 
organ showing the highest uptake of paclitaxel at the begin-
ning but the uptake had decreased rapidly to lower than tumor 
levels by 16 hours post injection. The results of radioimaging 
and biodistribution of the loaded drug support potential use 
of the PEG5kCA8 NM system as a promising nanocarrier for 
imaging-guided drug delivery.
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